Ignite Creation Date:
2025-12-24 @ 10:34 PM
Ignite Modification Date:
2025-12-25 @ 8:06 PM
Study NCT ID:
NCT06181435
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-10
First Post:
2023-12-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003876', 'term': 'Dermatitis, Atopic'}], 'ancestors': [{'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D003872', 'term': 'Dermatitis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D017443', 'term': 'Skin Diseases, Eczematous'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 589}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2023-12-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-03-18', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-03', 'studyFirstSubmitDate': '2023-12-13', 'studyFirstSubmitQcDate': '2023-12-13', 'lastUpdatePostDateStruct': {'date': '2025-12-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2023-12-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-11-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24', 'timeFrame': 'Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24', 'timeFrame': 'Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.'}, {'measure': 'US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24', 'timeFrame': 'Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}], 'secondaryOutcomes': [{'measure': 'Proportion of participants reaching EASI-75 at Week 24 (for US and US reference countries only)', 'timeFrame': 'Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with vIGA-AD 0 (clear) or 1 (almost clear) with presence of only barely perceptible erythema (no induration/papulation, no lichenification, no oozing or crusting) and a reduction from baseline of ≥2 points', 'timeFrame': 'Baseline to Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'Proportion of participants with ≥4-point reduction in weekly average of daily Peak Pruritus-Numerical Rating Scale (PP-NRS) from baseline in participants with baseline weekly average of daily PP-NRS ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Proportion of participants reaching EASI-75', 'timeFrame': 'Baseline to Week 20', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-75 is 75% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points', 'timeFrame': 'Baseline to Week 20', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'Proportion of participants with vIGA-AD 0 (clear)', 'timeFrame': 'Week 24', 'description': 'The vIGA-AD is an Investigator-completed assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale, ranging from 0 (clear) to 4 (severe).'}, {'measure': 'Proportion of participants reaching EASI-90', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-90 is 90% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants reaching EASI-100', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-100 is 100% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with PP-NRS 0 or 1', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Change in Dermatology Life Quality Index (DLQI) from baseline in participants with age ≥16 years old', 'timeFrame': 'Baseline to Week 24', 'description': 'The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Proportion of participants with a reduction in DLQI ≥4 from baseline in participants with age ≥16 years old and with DLQI baseline ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The DLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in adult patients. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Change in Children Dermatology Life Quality Index (CDLQI) from baseline in participants with age ≥12 to <16 years old', 'timeFrame': 'Baseline to Week 24', 'description': 'The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL.'}, {'measure': 'Proportion of participants with a reduction in CDLQI ≥6 from baseline in participants with age ≥12 to <16 years old and with CDLQI baseline ≥6', 'timeFrame': 'Baseline to Week 24', 'description': 'The CDLQI is a validated 10-item questionnaire to measure dermatology-specific quality of life (QoL) in children aged 4-\\<16 years. Overall scoring ranges from 0 to 30, with a higher score indicating a poorer QoL'}, {'measure': 'Change in Hospital Anxiety Depression Scale (HADS) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The HADS is 14-item questionnaire with two subscales: anxiety \\& depression. Each subscale (anxiety \\& depression) ranges 0-21. The total HADS score ranges 0-42 with higher score indicating a poorer state.'}, {'measure': 'Proportion of participants with HADS subscale Anxiety (HADS-A) <8 in participants with baseline HADS-A ≥8', 'timeFrame': 'Baseline to Week 24', 'description': 'HADS-A score ranges 0-21 with higher score indicating a poorer state.'}, {'measure': 'Proportion of participants with HADS subscale Depression (HADS-D) <8 in participants with HADS-D baseline ≥8', 'timeFrame': 'Baseline to Week 24', 'description': 'HADS-D score ranges 0-21 with higher score indicating a poorer state.'}, {'measure': 'Absolute change in weekly average of daily Skin Pain-Numerical Rating Scale (SP-NRS) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.'}, {'measure': 'Proportion of participants with a reduction in weekly average of daily SP-NRS ≥4 from baseline in participants with baseline weekly average of daily SP-NRS ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.'}, {'measure': 'Absolute change in weekly average of daily Sleep Disturbance-Numerical Rating Scale (SD-NRS) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.'}, {'measure': 'Proportion of participants with a reduction in weekly average of daily SD-NRS ≥3 from baseline in participants with Baseline weekly average of daily SD-NRS ≥3', 'timeFrame': 'Baseline to Week 24', 'description': 'The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.'}, {'measure': 'Percent change in weekly average of daily SP-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SP-NRS is a single item 0-10 numeric rating scale assessing skin pain associated with AD with 0 = no pain and 10 = worst possible pain imaginable.'}, {'measure': 'Percent change in weekly average of daily SD-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SD-NRS is a single item 0-10 numeric rating scale assessing sleep disturbance associated with AD with 0 = no sleep loss and 10 = did not sleep at all.'}, {'measure': 'Percent change in EASI score from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.'}, {'measure': 'Percent change in weekly average of daily PP-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Absolute change in weekly average of daily PP-NRS from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The PP-NRS is a validated single item 0-10 numeric rating scale assessing peak pruritus (itch) associated with AD with 0 = no itch and 10 = worst itch imaginable.'}, {'measure': 'Proportion of participants reaching EASI-50', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD. EASI-50 is 50% reduction from baseline in EASI score.'}, {'measure': 'Proportion of participants with EASI ≤7', 'timeFrame': 'Baseline to Week 24', 'description': 'The EASI is an Investigator-assessed validated tool used to measure the extent (area) and severity of AD. Total score ranges from 0 to 72 with a higher score indicating increased extent and severity of AD.'}, {'measure': 'Change in percent Body Surface Area (BSA) affected by AD from baseline', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Percent change in Scoring Atopic Dermatitis (SCORAD) index from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).'}, {'measure': 'Absolute change in SCORAD index from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).'}, {'measure': 'Proportion of participants with a reduction in SCORAD ≥ 8.7 points from baseline in participants with baseline SCORAD score ≥ 8.7', 'timeFrame': 'Baseline to Week 24', 'description': 'The SCORAD index is a clinical tool to evaluate the extent and severity of AD. Total score ranges from 0 (absent disease) to 103 (severe disease).'}, {'measure': 'Change in Patient Oriented Eczema Measure (POEM) from baseline', 'timeFrame': 'Baseline to Week 24', 'description': 'The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.'}, {'measure': 'Proportion of participants with a reduction in POEM ≥4 from baseline in participants with POEM Baseline ≥4', 'timeFrame': 'Baseline to Week 24', 'description': 'The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a 5-point scale; 0 (no days) to 4 (every day in the last week). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (very severe). Higher scores indicated more severe disease and poor quality of life.'}, {'measure': 'Proportion of participants with rescue medication use', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Percentage of participants who experience Treatment-Emergent Adverse Events (TEAEs), experience Treatment-Emergent Serious Adverse Events (TESAEs) and/or Treatment- Emergent Adverse Events of Special Interest (AESI)', 'timeFrame': 'Baseline to Week 40'}, {'measure': 'Serum amlitelimab concentrations', 'timeFrame': 'Baseline to Week 40'}, {'measure': 'Incidence of antidrug antibodies (ADAs) of amlitelimab', 'timeFrame': 'Baseline to Week 40'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Dermatitis Atopic']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.trialsummaries.com/Study/StudyDetails?id=25575&tenant=MT_SNY_9011', 'label': 'EFC17560 Plain Language Results Summary'}]}, 'descriptionModule': {'briefSummary': 'This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.\n\nThe purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participants with moderate to severe AD aged 12 years and older.\n\nStudy details include:\n\nAt the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY).\n\nFor participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up.\n\nFor participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period.\n\nThe total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Participants must be 12 years of age (when signing informed consent form)\n* Diagnosis of AD for at least 1 year (defined by the American Academy of Dermatology Consensus Criteria)\n* Documented history (within 6 months before screening) of either inadequate response or inadvisability to topical treatments, and/or inadequate response to systemic therapies (within 12 months before screening)\n* v-IGA-AD of 3 or 4 at baseline visit\n* EASI score of 16 or higher at baseline\n* AD involvement of 10% or more of BSA at baseline\n* Weekly average of daily PP-NRS of ≥ 4 at baseline visit.\n* Able and willing to comply with requested study visits and procedures\n* Body weight ≥ 25 kg\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Skin co-morbidity that would adversely affect the ability to undertake AD assessments\n* Known history of or suspected significant current immunosuppression\n* Any malignancies or history of malignancies prior to baseline (with the exception of non-melanoma skin cancer excised and cured \\>5 years prior to baseline)\n* History of solid organ or stem cell transplant\n* Any active or chronic infection including helminthic infection requiring systemic treatment within 4 weeks prior to baseline\n* Positive for human immunodeficiency virus (HIV), Hepatitis B or hepatitis C at screening visit\n* Having active tuberculosis (TB), latent TB, a history of incompletely treated TB, suspected extrapulmonary TB infection, or who are at high risk of contracting TB\n* Having received any of the specified therapy within the specified timeframe(s) prior to the baseline visit\n* In the Investigator's opinion, any clinically significant laboratory results or protocol specified laboratory abnormalities at screening\n* History of hypersensitivity or allergy to any of the excipients or investigational medicinal product (IMP)\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."}, 'identificationModule': {'nctId': 'NCT06181435', 'briefTitle': 'A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Sanofi'}, 'officialTitle': 'A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis', 'orgStudyIdInfo': {'id': 'EFC17560'}, 'secondaryIdInfos': [{'id': '2023-506557-38', 'type': 'REGISTRY', 'domain': 'CTIS'}, {'id': 'U1111-1275-9665', 'type': 'REGISTRY', 'domain': 'ICTRP'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Amlitelimab dose 1', 'description': 'Subcutaneous injection as per protocol', 'interventionNames': ['Drug: Amlitelimab']}, {'type': 'EXPERIMENTAL', 'label': 'Amlitelimab dose 2', 'description': 'Subcutaneous injection as per protocol', 'interventionNames': ['Drug: Amlitelimab']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Subcutaneous injection as per protocol', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Amlitelimab', 'type': 'DRUG', 'otherNames': ['SAR445229'], 'description': 'Pharmaceutical form: Injection solution Route of administration: SC injection', 'armGroupLabels': ['Amlitelimab dose 1', 'Amlitelimab dose 2']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Pharmaceutical form:\n\nInjection solution Route of administration: SC injection', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85260', 'city': 'Scottsdale', 'state': 'Arizona', 'country': 'United States', 'facility': 'Center for Dermatology and Plastic Surgery- Site Number : 8401119', 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'zip': '85745', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'Eclipse Clinical Research- Site Number : 8401158', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '90717', 'city': 'Lomita', 'state': 'California', 'country': 'United States', 'facility': 'Torrance Clinical Research- Site Number : 8401027', 'geoPoint': {'lat': 33.79224, 'lon': -118.31507}}, {'zip': '90045', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Dermatology Research Associates - Los Angeles- Site Number : 8401092', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92691', 'city': 'Mission Viejo', 'state': 'California', 'country': 'United States', 'facility': 'Allergy & Asthma Associates of Southern California - Mission Viejo- Site Number : 8401079', 'geoPoint': {'lat': 33.60002, 'lon': -117.672}}, {'zip': '93030', 'city': 'Oxnard', 'state': 'California', 'country': 'United States', 'facility': 'Cura Clinical Research - Oxnard- Site Number : 8401142', 'geoPoint': {'lat': 34.1975, 'lon': -119.17705}}, {'zip': '90404', 'city': 'Santa Monica', 'state': 'California', 'country': 'United States', 'facility': 'Clinical Science Institute- Site Number : 8401028', 'geoPoint': {'lat': 34.01949, 'lon': -118.49138}}, {'zip': '06032', 'city': 'Farmington', 'state': 'Connecticut', 'country': 'United States', 'facility': 'University of Connecticut Health Center- Site Number : 8401115', 'geoPoint': {'lat': 41.71982, 'lon': -72.83204}}, {'zip': '33146', 'city': 'Coral Gables', 'state': 'Florida', 'country': 'United States', 'facility': 'Pediatric Skin Research- Site Number : 8401198', 'geoPoint': {'lat': 25.72149, 'lon': -80.26838}}, {'zip': '33021', 'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'facility': 'Skin Care Research - Hollywood- Site Number : 8401071', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'zip': '33126', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Savin Medical Group - Miami- Site Number : 8401085', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33176', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Anchor Medical Research- Site Number : 8401300', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32829', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Accel Research - Nona Pediatric Center- Site Number : 8401081', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33060', 'city': 'Pompano Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Nuline Clinical Trial Center- Site Number : 8401161', 'geoPoint': {'lat': 26.23786, 'lon': -80.12477}}, {'zip': '33607', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Research Trials of Florida- Site Number : 8401023', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '31904', 'city': 'Columbus', 'state': 'Georgia', 'country': 'United States', 'facility': 'AllerVie Clinical Research - Columbus- Site Number : 8401104', 'geoPoint': {'lat': 32.46098, 'lon': -84.98771}}, {'zip': '30214', 'city': 'Fayetteville', 'state': 'Georgia', 'country': 'United States', 'facility': 'First Georgia Physician Group- Site Number : 8401190', 'geoPoint': {'lat': 33.44873, 'lon': -84.45493}}, {'zip': '42104', 'city': 'Bowling Green', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Access Dermatology- Site Number : 8401296', 'geoPoint': {'lat': 36.99032, 'lon': -86.4436}}, {'zip': '70433', 'city': 'Covington', 'state': 'Louisiana', 'country': 'United States', 'facility': 'MedPharmics - Covington- Site Number : 8401137', 'geoPoint': {'lat': 30.47549, 'lon': -90.10042}}, {'zip': '21104', 'city': 'Marriottsville', 'state': 'Maryland', 'country': 'United States', 'facility': 'Care Access Research - Marriottsville- Site Number : 8401126', 'geoPoint': {'lat': 39.3501, 'lon': -76.89942}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Tufts Medical Center Site Number : 8401201', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '39216', 'city': 'Jackson', 'state': 'Mississippi', 'country': 'United States', 'facility': 'University Of Mississippi Medical Center- Site Number : 8401184', 'geoPoint': {'lat': 32.29876, 'lon': -90.18481}}, {'zip': '07030', 'city': 'Hoboken', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Care Access - Hoboken- Site Number : 8401132', 'geoPoint': {'lat': 40.74399, 'lon': -74.03236}}, {'zip': '87102', 'city': 'Albuquerque', 'state': 'New Mexico', 'country': 'United States', 'facility': 'University of New Mexico Comprehensive Cancer Center- Site Number : 8401263', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'zip': '11220', 'city': 'Brooklyn', 'state': 'New York', 'country': 'United States', 'facility': 'OmeraNY- Site Number : 8401156', 'geoPoint': {'lat': 40.6501, 'lon': -73.94958}}, {'zip': '10023', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Equity Medical- Site Number : 8401239', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '10467', 'city': 'The Bronx', 'state': 'New York', 'country': 'United States', 'facility': 'Montefiore Medical Center - Moses Campus- Site Number : 8401150', 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'zip': '58103', 'city': 'Fargo', 'state': 'North Dakota', 'country': 'United States', 'facility': 'Red River Research Partners- Site Number : 8401196', 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'zip': '43209', 'city': 'Bexley', 'state': 'Ohio', 'country': 'United States', 'facility': 'Bexley Dermatology Research- Site Number : 8401051', 'geoPoint': {'lat': 39.96895, 'lon': -82.93768}}, {'zip': '45246', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Velocity Clinical Research - Springdale- Site Number : 8401153', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '19462', 'city': 'Plymouth Meeting', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Dermatology Associates of Plymouth Meeting- Site Number : 8401147', 'geoPoint': {'lat': 40.10233, 'lon': -75.27435}}, {'zip': '15241', 'city': 'Upper Saint Clair', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'PEAK Research- Site Number : 8401083', 'geoPoint': {'lat': 40.3359, 'lon': -80.08339}}, {'zip': '29212', 'city': 'Columbia', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Columbia Dermatology & Aesthetics- Site Number : 8401166', 'geoPoint': {'lat': 34.00071, 'lon': -81.03481}}, {'zip': '57702', 'city': 'Rapid City', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Health Concepts- Site Number : 8401059', 'geoPoint': {'lat': 44.08054, 'lon': -103.23101}}, {'zip': '76011', 'city': 'Arlington', 'state': 'Texas', 'country': 'United States', 'facility': 'Arlington Research Center- Site Number : 8401248', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Derm Texas- Site Number : 8401217', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77004', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Center for Clinical Studies - Houston - Binz Street- Site Number : 8401063', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77054', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Prolato Clinical Research Center- Site Number : 8401209', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77459', 'city': 'Missouri City', 'state': 'Texas', 'country': 'United States', 'facility': 'Sienna Dermatology- Site Number : 8401148', 'geoPoint': {'lat': 29.61857, 'lon': -95.53772}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Progressive Clinical Research - San Antonio- Site Number : 8401016', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '84405', 'city': 'Ogden', 'state': 'Utah', 'country': 'United States', 'facility': 'Advanced Research Institute - Odgen- Site Number : 8401057', 'geoPoint': {'lat': 41.223, 'lon': -111.97383}}, {'zip': '22206', 'city': 'Arlington', 'state': 'Virginia', 'country': 'United States', 'facility': 'Care Access - Arlington- Site Number : 8401134', 'geoPoint': {'lat': 38.88101, 'lon': -77.10428}}, {'zip': '23666', 'city': 'Hampton', 'state': 'Virginia', 'country': 'United States', 'facility': 'Velocity Clinical Research - Hampton- Site Number : 8401154', 'geoPoint': {'lat': 37.02987, 'lon': -76.34522}}, {'zip': '1886', 'city': 'Berazategui', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320021', 'geoPoint': {'lat': -34.76531, 'lon': -58.21278}}, {'zip': '1629', 'city': 'Pilar', 'state': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320017', 'geoPoint': {'lat': -34.45867, 'lon': -58.91398}}, {'zip': '2000', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320006', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': '2000', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320007', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': '2000', 'city': 'Rosario', 'state': 'Santa Fe Province', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320015', 'geoPoint': {'lat': -32.94682, 'lon': -60.63932}}, {'zip': '1055', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320016', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '1121', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320001', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '1425', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320002', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '1425', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Investigational Site Number : 0320009', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '5300', 'city': 'Gabrovo', 'country': 'Bulgaria', 'facility': 'Investigational Site Number : 1002008', 'geoPoint': {'lat': 42.87419, 'lon': 25.31823}}, {'zip': '5800', 'city': 'Pleven', 'country': 'Bulgaria', 'facility': 'Investigational Site Number : 1002004', 'geoPoint': {'lat': 43.41791, 'lon': 24.61666}}, {'zip': '1431', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Investigational Site Number : 1002005', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '5110683', 'city': 'Valdivia', 'state': 'Los Ríos Region', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520004', 'geoPoint': {'lat': -39.81422, 'lon': -73.24589}}, {'zip': '7500505', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520013', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7640881', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520003', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '7750495', 'city': 'Santiago', 'state': 'Reg Metropolitana de Santiago', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520014', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '2260877', 'city': 'Quillota', 'state': 'Región de Valparaíso', 'country': 'Chile', 'facility': 'Investigational Site Number : 1520015', 'geoPoint': {'lat': -32.88341, 'lon': -71.24882}}, {'zip': '100191', 'city': 'Beijing', 'country': 'China', 'facility': 'Investigational Site Number : 1560004', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100730', 'city': 'Beijing', 'country': 'China', 'facility': 'Investigational Site Number : 1560030', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '610041', 'city': 'Chengdu', 'country': 'China', 'facility': 'Investigational Site Number : 1560022', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '510018', 'city': 'Guangzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560021', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '510080', 'city': 'Guangzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560025', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '310006', 'city': 'Hangzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560002', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '310009', 'city': 'Hangzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560006', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '310014', 'city': 'Hangzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560029', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '250013', 'city': 'Jinan', 'country': 'China', 'facility': 'Investigational Site Number : 1560007', 'geoPoint': {'lat': 36.66833, 'lon': 116.99722}}, {'zip': '315010', 'city': 'Ningbo', 'country': 'China', 'facility': 'Investigational Site Number : 1560024', 'geoPoint': {'lat': 29.87819, 'lon': 121.54945}}, {'zip': '200040', 'city': 'Shanghai', 'country': 'China', 'facility': 'Investigational Site Number : 1560001', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '200443', 'city': 'Shanghai', 'country': 'China', 'facility': 'Investigational Site Number : 1560005', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '110179', 'city': 'Shenyang', 'country': 'China', 'facility': 'Investigational Site Number : 1560026', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'zip': '325035', 'city': 'Wenzhou', 'country': 'China', 'facility': 'Investigational Site Number : 1560023', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}, {'zip': '214000', 'city': 'Wuxi', 'country': 'China', 'facility': 'Investigational Site Number : 1560003', 'geoPoint': {'lat': 31.56887, 'lon': 120.28857}}, {'zip': '212000', 'city': 'Zhenjiang', 'country': 'China', 'facility': 'Investigational Site Number : 1560028', 'geoPoint': {'lat': 32.21086, 'lon': 119.45508}}, {'zip': '284 01', 'city': 'Kutná Hora', 'country': 'Czechia', 'facility': 'Investigational Site Number : 2032106', 'geoPoint': {'lat': 49.94839, 'lon': 15.26816}}, {'zip': '779 00', 'city': 'Olomouc', 'country': 'Czechia', 'facility': 'Investigational Site Number : 2030010', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'zip': '702 00', 'city': 'Ostrava', 'country': 'Czechia', 'facility': 'Investigational Site Number : 2032104', 'geoPoint': {'lat': 49.83465, 'lon': 18.28204}}, {'zip': '150 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Investigational Site Number : 2030011', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '160 00', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Investigational Site Number : 2030006', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '9000', 'city': 'Aalborg', 'country': 'Denmark', 'facility': 'Investigational Site Number : 2080002', 'geoPoint': {'lat': 57.048, 'lon': 9.9187}}, {'zip': '8200', 'city': 'Aarhus', 'country': 'Denmark', 'facility': 'Investigational Site Number : 2080001', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}, {'zip': '2730', 'city': 'Herlev', 'country': 'Denmark', 'facility': 'Investigational Site Number : 2080003', 'geoPoint': {'lat': 55.72366, 'lon': 12.43998}}, {'zip': '20089', 'city': 'Rozzano', 'state': 'Milano', 'country': 'Italy', 'facility': 'Investigational Site Number : 3800018', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'zip': '00133', 'city': 'Rome', 'state': 'Roma', 'country': 'Italy', 'facility': 'Investigational Site Number : 3800013', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '95123', 'city': 'Catania', 'country': 'Italy', 'facility': 'Investigational Site Number : 3800009', 'geoPoint': {'lat': 37.49223, 'lon': 15.07041}}, {'zip': '56126', 'city': 'Pisa', 'country': 'Italy', 'facility': 'Investigational Site Number : 3800008', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'zip': '36100', 'city': 'Vicenza', 'country': 'Italy', 'facility': 'Investigational Site Number : 3800022', 'geoPoint': {'lat': 45.54672, 'lon': 11.5475}}, {'zip': '066-0021', 'city': 'Chitose', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920009', 'geoPoint': {'lat': 42.81944, 'lon': 141.65222}}, {'zip': '080-0013', 'city': 'Obihiro', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923114', 'geoPoint': {'lat': 42.91722, 'lon': 143.20444}}, {'zip': '064-0921', 'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920008', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'zip': '653-0836', 'city': 'Kobe', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920006', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'zip': '252-0315', 'city': 'Sagamihara', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920005', 'geoPoint': {'lat': 35.56707, 'lon': 139.24167}}, {'zip': '221-0825', 'city': 'Yokohama', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923113', 'geoPoint': {'lat': 35.43333, 'lon': 139.65}}, {'zip': '981-0112', 'city': 'Miyagi-gun', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920010'}, {'zip': '981-3133', 'city': 'Sendai', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920011', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}, {'zip': '583-8588', 'city': 'Habikino', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923109', 'geoPoint': {'lat': 34.55276, 'lon': 135.59097}}, {'zip': '593-8324', 'city': 'Sakai', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923110', 'geoPoint': {'lat': 34.58216, 'lon': 135.46653}}, {'zip': '350-0495', 'city': 'Iruma', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920002', 'geoPoint': {'lat': 35.818, 'lon': 139.368}}, {'zip': '321-0293', 'city': 'Mibu', 'state': 'Tochigi', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923106', 'geoPoint': {'lat': 36.41667, 'lon': 139.8}}, {'zip': '104-0031', 'city': 'Chūō', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920004', 'geoPoint': {'lat': 35.67004, 'lon': 139.77544}}, {'zip': '108-0014', 'city': 'Minato', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923107', 'geoPoint': {'lat': 35.6581, 'lon': 139.7515}}, {'zip': '190-0023', 'city': 'Tachikawa', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920001', 'geoPoint': {'lat': 35.7091, 'lon': 139.41891}}, {'zip': '890-0063', 'city': 'Kagoshima', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923108', 'geoPoint': {'lat': 31.56667, 'lon': 130.55}}, {'zip': '602-8566', 'city': 'Kyoto', 'country': 'Japan', 'facility': 'Investigational Site Number : 3923102', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '606-8507', 'city': 'Kyoto', 'country': 'Japan', 'facility': 'Investigational Site Number : 3920003', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '64460', 'city': 'Monterrey', 'state': 'Nuevo León', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840011', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '64718', 'city': 'Monterrey', 'state': 'Nuevo León', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840005', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '20127', 'city': 'Aguascalientes', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840012', 'geoPoint': {'lat': 21.88262, 'lon': -102.2843}}, {'zip': '34000', 'city': 'Durango', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840009', 'geoPoint': {'lat': 24.02032, 'lon': -104.65756}}, {'zip': '91900', 'city': 'Veracruz', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840003', 'geoPoint': {'lat': 19.18095, 'lon': -96.1429}}, {'zip': '1169-050', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Investigational Site Number : 6200005', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1649-035', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Investigational Site Number : 6200004', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1998-018', 'city': 'Lisbon', 'country': 'Portugal', 'facility': 'Investigational Site Number : 6200001', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '4099-001', 'city': 'Porto', 'country': 'Portugal', 'facility': 'Investigational Site Number : 6200003', 'geoPoint': {'lat': 41.1485, 'lon': -8.61097}}, {'zip': '1459', 'city': 'Boksburg', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100004', 'geoPoint': {'lat': -26.21197, 'lon': 28.25958}}, {'zip': '7533', 'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100010', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '7708', 'city': 'Cape Town', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100009', 'geoPoint': {'lat': -33.92584, 'lon': 18.42322}}, {'zip': '3630', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100012', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '4058', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100001', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '1500', 'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100015', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '2196', 'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100007', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '0009', 'city': 'Pretoria', 'country': 'South Africa', 'facility': 'Investigational Site Number : 7100003', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '35010', 'city': 'Las Palmas de Gran Canaria', 'state': 'Las Palmas', 'country': 'Spain', 'facility': 'Investigational Site Number : 7240012', 'geoPoint': {'lat': 28.10178, 'lon': -15.41573}}, {'zip': '18014', 'city': 'Granada', 'country': 'Spain', 'facility': 'Investigational Site Number : 7240018', 'geoPoint': {'lat': 37.18817, 'lon': -3.60667}}, {'zip': '28007', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Investigational Site Number : 7240029', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Investigational Site Number : 7242503', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '125 44', 'city': 'Älvsjö', 'country': 'Sweden', 'facility': 'Investigational Site Number : 7520006', 'geoPoint': {'lat': 59.27689, 'lon': 18.00221}}, {'zip': '701 85', 'city': 'Örebro', 'country': 'Sweden', 'facility': 'Investigational Site Number : 7520001', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'zip': '07070', 'city': 'Antalya', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920001', 'geoPoint': {'lat': 36.90812, 'lon': 30.69556}}, {'zip': '34093', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920005', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34093', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920006', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '34098', 'city': 'Istanbul', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920002', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}, {'zip': '38039', 'city': 'Kayseri', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920004', 'geoPoint': {'lat': 38.73222, 'lon': 35.48528}}, {'zip': '33343', 'city': 'Mersin', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920011', 'geoPoint': {'lat': 36.81196, 'lon': 34.63886}}, {'zip': '55139', 'city': 'Samsun', 'country': 'Turkey (Türkiye)', 'facility': 'Investigational Site Number : 7920007', 'geoPoint': {'lat': 41.27976, 'lon': 36.3361}}, {'zip': 'PO3 6DW', 'city': 'Portsmouth', 'state': 'Hampshire', 'country': 'United Kingdom', 'facility': 'Investigational Site Number : 8260003', 'geoPoint': {'lat': 50.79899, 'lon': -1.09125}}, {'zip': 'SE1 7EH', 'city': 'London', 'state': 'London, City of', 'country': 'United Kingdom', 'facility': 'Investigational Site Number : 8262602', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE1 9RT', 'city': 'London', 'state': 'London, City of', 'country': 'United Kingdom', 'facility': 'Investigational Site Number : 8262601', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'G3 8SJ', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'Investigational Site Number : 8260006', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'LE2 0TA', 'city': 'Leicester', 'country': 'United Kingdom', 'facility': 'Investigational Site Number : 8260004', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}